Stock TZAC REVIVA PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Reviva Pharmaceuticals Holdings, Inc. Nasdaq

Equities

TZAC

US76152G1004

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
PR
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
PR
Reviva to Participate in the BIO International Convention
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
PR
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
AQ
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
AQ
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
AQ
RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
PR
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
PR
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
BU
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
AQ
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
AQ
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
AQ
Reviva to Present at the UBS Virtual CNS Day
AQ
Reviva to Present at the 36th Annual ROTH Conference
AQ
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
AQ
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVPH Stock
  4. TZAC Stock
  5. News Reviva Pharmaceuticals Holdings, Inc.
  6. Press Releases